Stock Market News
Amryt Pharma signs distribution agreement for Lojuxta in Switzerland
Biopharmaceutical group Amryt Pharma has signed an exclusive distributor agreement for Lojuxta, its treatment for homozygous familial hypercholesterolemia (HoFH) - a rare, life-limiting disease that impairs the body's ability to remove bad cholesterol from the blood - in Switzerland.
The agreement is with Swiss pharmaceutical company RCC Pharma, which focuses on early access programmes in rare and orphan diseases. The company, which currently estimates that there are around 15 patients with HoFH in Switzerland, has received requests from clinicians for access to Lojuxta for Swiss patients and this agreement will now enable Amryt to respond more effectively to such requests.
The new agreement follows a distribution agreement, announced on 13 November, which covers Amryt's products for the Kingdom of Saudi Arabia.
Chief executive officer Joe Wiley said: "This new distribution agreement with RCC marks another key step as we expand our footprint for Lojuxta across Europe, the Middle East, and North Africa. RCC is a leading Swiss company with particular expertise in rare diseases, and this agreement will help us to bring Lojuxta to patients suffering from HoFH in Switzerland.
"We continue to work on further partnerships across our licensed territories for Lojuxta, and look forward to announcing further developments."
HoFH starts before birth and progresses rapidly, typically resulting in extremely high blood LDL cholesterol levels, which leads to aggressive and premature narrowing and blocking of blood vessels. Left untreated, heart attack or sudden death may occur in childhood or early adulthood.
At 1400 GMT, the shares were down 0.1% to 19.68p.
The agreement is with Swiss pharmaceutical company RCC Pharma, which focuses on early access programmes in rare and orphan diseases. The company, which currently estimates that there are around 15 patients with HoFH in Switzerland, has received requests from clinicians for access to Lojuxta for Swiss patients and this agreement will now enable Amryt to respond more effectively to such requests.
The new agreement follows a distribution agreement, announced on 13 November, which covers Amryt's products for the Kingdom of Saudi Arabia.
Chief executive officer Joe Wiley said: "This new distribution agreement with RCC marks another key step as we expand our footprint for Lojuxta across Europe, the Middle East, and North Africa. RCC is a leading Swiss company with particular expertise in rare diseases, and this agreement will help us to bring Lojuxta to patients suffering from HoFH in Switzerland.
"We continue to work on further partnerships across our licensed territories for Lojuxta, and look forward to announcing further developments."
HoFH starts before birth and progresses rapidly, typically resulting in extremely high blood LDL cholesterol levels, which leads to aggressive and premature narrowing and blocking of blood vessels. Left untreated, heart attack or sudden death may occur in childhood or early adulthood.
At 1400 GMT, the shares were down 0.1% to 19.68p.
Related share prices |
---|
Amryt Pharma (AMYT) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price